secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-037627
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon reports Q4 2023 net loss of $19.3M; cash runway into Q4 2025
--------------------------------------------------------------------

- Net loss Q4 2023 $19.3M, full year $60.4M; R&D expenses $15.5M/$46.0M.
- Cash, equivalents and marketable securities $127.5M at Dec 31, 2023; funds operations into Q4 2025.
- ACR-368 Phase 2 trial enrolling; Phase 1b combo with gemcitabine completed; ACR-2316 IND studies advancing.
- Two abstracts accepted for AACR 2024 on ACR-2316 and ACR-368 resistance mechanism.
- Appointed Jean-Marie Cuillerot as CMO; added two new board members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024037627/0000950170-24-037627-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024037627/acrv-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-037627

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer